Mizuho raised the firm’s price target on Staar Surgical to $53 from $45 and keeps a Buy rating on the shares ahead of the Q1 report. The analyst cites the “strong” pre-announcement on China and U.S. trends for the target increase.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical price target raised to $46 from $32 at Canaccord
- Staar Surgical upgraded to Outperform after Q1 beat at William Blair
- Staar Surgical upgraded to Outperform from Market Perform at William Blair
- Staar Surgical reports preliminary Q1 revenue in excess of $77M, consensus $72M
- Staar Surgical Highlights Milestone and Investor Engagement
